Chronic spontaneous urticaria treated with omalizumab: report of two cases
Background: Chronic spontaneous urticaria (CSU) is a relatively common skin disease whose etiopathogenesis, as well as other factors influencing disease manifestations, are not fully understood. Mast cell function is recognised as having a central role in CSU signs and symptoms. Therapeutic options...
Main Authors: | Giovanna Malara, Claudio Sciarrone |
---|---|
Format: | Article |
Language: | English |
Published: |
Taylor & Francis Group
2018-12-01
|
Series: | Journal of Dermatological Treatment |
Subjects: | |
Online Access: | http://dx.doi.org/10.1080/09546634.2018.1551608 |
Similar Items
-
Omalizumab in the treatment of chronic spontaneous urticaria – literature review and own experience
by: Joanna Dawicka, et al.
Published: (2016-02-01) -
Omalizumab treatment in a 12 year-old girl with chronic spontaneous urticaria
by: Giuseppe Fabio Parisi, et al.
Published: (2018-12-01) -
Omalizumab for the management of refractory chronic spontaneous urticaria
by: P C Kathuria, et al.
Published: (2022-01-01) -
Omalizumab treatment for chronic spontaneous urticaria: data from Turkey
by: Rabia Kara, et al.
Published: (2022-09-01) -
COVID-19 infection in chronic spontaneous urticaria treated with omalizumab: two case reports
by: Angelo Massimiliano D'Erme, et al.
Published: (2023-08-01)